{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-26-000012","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.999891+00:00","generated_at":"2026-05-15T09:11:08.189649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurogene reports FY2025 net loss $90.4M, cash $269M; NGN-401 dosing on track","bullets":["Net loss $90.4M in FY2025 vs $75.1M in FY2024; cash $269M funds through Q1 2028.","100% enrolled in Embolden registrational trial for Rett syndrome; >50% dosed; on track to complete dosing Q2 2026.","NGN-401 generally well-tolerated at 1E15 vg dose, no HLH cases; FDA Breakthrough Therapy designation granted.","R&D expenses $75.0M up from $60.9M; G&A $28.3M up from $22.6M.","Key milestones: interim Phase 1/2 data mid-2026, PPQ campaign mid-2026, BLA submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-26-000012","json":"https://secwatch.observer/filing/0001404644-26-000012.json","markdown":"https://secwatch.observer/filing/0001404644-26-000012.md","text":"https://secwatch.observer/filing/0001404644-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/0001404644-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/ngne-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:11:08.189649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7366dedb267ab01eeba9a39ceac2762d14cb8c8e","claim":"Neurogene Inc. reported twelve months ended December 31, 2025 results: net income -90.4 million.","evidence_excerpt":"Full Year 2025 Financial Results • Cash, Cash Equivalents and Short-Term Investments : Cash, cash equivalents and short-term investments as of December 31, 2025 were $269.0 million and are expected to fund planned operations through the first quarter of 2028. • Research & Development (R&D) Expenses : R&D expenses were $75.0 million for the twelve months ended December 31, 2025, compared to $60.9 million for the twelve months ended December 31, 2024. The increase in R&D expenses for the twelve months ended December 31, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount, and it was partially offset by decreases in spending on the CLN5 Batten disease program and early discovery. • General & Administrative (G&A) Expenses : G&A expenses were $28.3 million for the twelve months ended December 31, 2025, compared to $22.6 million for the twelve months ended December 31, 2024. The increase in G&A expen","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/0001404644-26-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended December 31, 2025"},{"label":"Net income","value":"-90.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}